News

Dr. Lee highlights the process of identifying CTEPH and the patient population, as well as the available treatments for the condition.

The decision represents the first ever upadacitinib for a gastroenterological disease.

Rhythm Pharmaceuticals shares data from long-term extension study of setmelanotide in Bardet-Biedl Syndrome.

Investigators believe these results may aid shared decision-making between clinicians and patients.

Social media has had an influence on the mental health toll the war in the Ukraine is having.

Approximately 60% of patients with ulcerative colitis treated with guselkumab achieved clinical remission.

Apixaban prescription beyond 90 days showed no difference in hospitalization risk for major bleeding.

New data show the highest quintile of census-reported parental income is far more represented among future physicians than lower income levels, regardless of race.

Internalized skin bias also appeared to mediate the associations of depression and anxiety related to health-related quality of life.

ChristianaCare’s Gene Editing Institute experts join the podcast to discuss the latest developments in gene editing.

An analysis of the EUROSTAD study found that the median duration of treatment with the biologic was 14 months.

The inhaler is approved for 2 strengths, 160/4.5 mcg/actuation and 80/4.5 mcg/actuation.

Novartis announces promising results from research evaluating the safety and efficacy of Zolgensma.

Children with unconfirmed PALs have prolonged hospital stays, higher rates of adverse events, and more infections due to Clostridium difficile and vancomycin-resistant Enterococcus.

The recurrent CDI cohort were nearly 10 times likelier to suffer from a CDI-associated death than the primary CDI cohort.

Data show LNCSBs as a substitute for sugar-sweetened beverages were associated with reduced body weight, BMI, percentage of body fat, and intrahepatocellular lipid.

A new post-hoc analyses for the sodium oxybate FT218 found that the therapy improved daytime sleepiness, sleep quality, and refreshing nature of sleep in patients with narcolepsy.

USPSTF experts noted a need for research into the benefits and harms of screening adults and adolescents without signs or symptoms.

Data show the absolute risk reductions of treatment with statins in terms of all-cause mortality, myocardial infarction, and stroke are modest compared with the relative risk reductions.

More studies need to be done examining the associations of increased weight and outcomes among patients with cystic fibrosis.

Digital cognitive behavioral therapy for insomnia was the better option to patient education on all ratings for patients with self-reported morning or intermediate chronotypes.

Patients with obstructive sleep apnea had higher levels of inflammatory biomarkers of IL-6, TNF-α, and hsCRP levels compared to the control group.

The results of meta-analysis showed that telemedicine methods were more effective in treating chronic insomnia than in-person methods.

Dr. Avidan speaks of the increased prevalence of insomnia and sleep-wake patterns and promising new therapies for sleep disorders including narcolepsy.

Consistent quantitative evidence of sleep disturbance in this population has been associated with staff distress, resident agitation, and prescription of psychotropic medications.

Dr. Garcia-Molina speaks to how smart bed technology can unobtrusively collect data to predict and track the development of symptoms associated with respiratory illnesses.

Geriatric dermatology is an emerging field in the world of skin studies, with complications including cognition, polypharmacy, mobility, social support, and sleep disturbance affecting access to care.

Findings suggest mortality risk from the respiratory virus is twice greater among adults with CHF.